Ascendis Pharma A/S (ASND) to Release Earnings on Thursday

Key Points

• Ascendis Pharma A/S is set to release its quarterly earnings on Thursday, August 7th, with analysts expecting a loss of ($1.42) per share and revenue of $163.17 million.
• The company recently reported a loss of ($1.66) EPS in its last quarter, missing the consensus estimate but exceeding revenue expectations with $123.97 million.
• Analysts maintain a consensus rating of "Moderate Buy" for Ascendis Pharma A/S, with a price target averaging $223.67, indicating optimism for future performance.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.42) per share and revenue of $163.17 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Up 0.6%

Ascendis Pharma A/S stock opened at $174.48 on Friday. The company has a market cap of $10.67 billion, a P/E ratio of -27.78 and a beta of 0.41. The company has a fifty day simple moving average of $171.44 and a 200 day simple moving average of $157.05. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ASND shares. Oppenheimer restated an "outperform" rating and issued a $224.00 target price (up from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Royal Bank Of Canada boosted their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $245.00 to $254.00 and gave the company an "overweight" rating in a research report on Tuesday, July 29th. Finally, Citigroup boosted their target price on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research report on Friday, July 11th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $223.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.